35 Advanced Solid Tumors Clinical Trials in Duarte, CA (2026)

Q: How do I join a clinical trial in Duarte?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Duarte research site will contact you.

Recruiting Advanced Solid Tumors Studies in Duarte

NCT06172478Recruiting

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma ...

Duarte, CAPHASE2740 participantsDaiichi Sankyo

View Study Details

NCT05382559Recruiting

A Study of ASP3082 in Adults With Advanced Solid Tumors

This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people...

Duarte, CAPHASE1681 participantsAstellas Pharma Inc

View Study Details

NCT05238922Recruiting

Study of INCB123667 in Subjects With Advanced Solid Tumors

This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and...

Duarte, CAPHASE1604 participantsIncyte Corporation

View Study Details

NCT07522073Recruiting

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC)....

Duarte, CAPHASE3588 participantsIncyte Corporation

View Study Details

NCT03093116Recruiting

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotre...

Duarte, CAPHASE1500 participantsTurning Point Therapeutics, Inc.

View Study Details

NCT06311214Recruiting

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

This phase II ADC MATCH screening and multi-sub-study treatment trial is evaluating whether biomarker-directed treatment with one of three antibody-drug conjugates (ADCs) (sacituzumab govitecan, enfor...

Duarte, CAPHASE2500 participantsNational Cancer Institute (NCI)

View Study Details

NCT06384807Recruiting

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors....

Duarte, CAPHASE1500 participantsBiohaven Therapeutics Ltd.

View Study Details

NCT05123482Recruiting

A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies

This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents...

Duarte, CAPHASE1460 participantsAstraZeneca

View Study Details

NCT06914128Recruiting

A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors

The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferas...

Duarte, CAPHASE1450 participantsBayer

View Study Details

NCT07094113Recruiting

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AMG 410 when administered alone or in combin...

Duarte, CAPHASE1434 participantsAmgen

View Study Details

NCT06465069Recruiting

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The ...

Duarte, CAPHASE1420 participantsEli Lilly and Company

View Study Details

NCT06625775Recruiting

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced...

Duarte, CAPHASE1392 participantsTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

View Study Details

NCT05315700Recruiting

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-...

Duarte, CAPHASE1350 participantsORIC Pharmaceuticals

View Study Details

NCT06265727Recruiting

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to answe...

Duarte, CAPHASE1348 participantsCorbus Pharmaceuticals Inc.

View Study Details

NCT06596473Recruiting

A Study of BG-C477 in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in ...

Duarte, CAPHASE1310 participantsBeOne Medicines

View Study Details

NCT07090499Recruiting

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-0...

Duarte, CAPHASE1310 participantsPfizer

View Study Details

NCT06004245Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumo...

Duarte, CAPHASE1280 participantsVividion Therapeutics, Inc.

View Study Details

NCT07195916Recruiting

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies....

Duarte, CAPHASE1280 participantsIncyte Corporation

View Study Details

NCT04939610Recruiting

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

Fibroblast activation protein (FAP) is a cell surface protein that is highly expressed on the surface of cancer-associated fibroblasts (CAFs) present in the tumor microenvironment of most epithelial c...

Duarte, CAPHASE1222 participantsNovartis Pharmaceuticals

View Study Details

NCT05981703Recruiting

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced so...

Duarte, CAPHASE1217 participantsBeOne Medicines

View Study Details

NCT04981119Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible p...

Duarte, CA200 participantsA2 Biotherapeutics Inc.

View Study Details

NCT05405595Recruiting

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

This is a Phase 1b/2, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of ADG126-pembrolizumab combination regimens in patients with advanced/metastatic s...

Duarte, CAPHASE1186 participantsAdagene Inc

View Study Details

NCT07432295Recruiting

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

The goal of this clinical trial is to learn if givastomig in combination with standard therapy works to treat adults with cancer in the stomach and/or esophagus (GEA adenocarcinoma). It will also help...

Duarte, CAPHASE2180 participantsI-Mab Biopharma US Limited

View Study Details

NCT04752826Recruiting

BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced malignancies whose disease has progressed...

Duarte, CAPHASE1176 participantsBioInvent International AB

View Study Details

NCT07197554Recruiting

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies...

Duarte, CAPHASE1171 participantsSEED Therapeutics, Inc.

View Study Details

NCT06657144Recruiting

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanc...

Duarte, CAPHASE1154 participantsCoherus Oncology, Inc.

View Study Details

NCT06760819Recruiting

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to ...

Duarte, CAPHASE2111 participantsBayer

View Study Details

NCT06266299Recruiting

A Study of KK2269 in Adult Participants With Solid Tumors

This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study. Participants with advanced or metastatic solid tumors...

Duarte, CAPHASE1101 participantsKyowa Kirin Co., Ltd.

View Study Details

NCT06399757Recruiting

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus o...

Duarte, CAPHASE1100 participantsApollo Therapeutics Ltd

View Study Details

NCT04762641Recruiting

This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors

This is a first-in-human Phase 1, single-arm, open-label, multicenter, multiple-dose, dose-escalation and dose-expansion study of ABL503 to evaluate the safety, tolerability, MTD and/or RP2D, PK, immu...

Duarte, CAPHASE1100 participantsABL Bio, Inc.

View Study Details

NCT07196644Recruiting

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab ad...

Duarte, CAPHASE2100 participantsAbbVie

View Study Details

NCT05327010Recruiting

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with treatment a...

Duarte, CAPHASE288 participantsNational Cancer Institute (NCI)

View Study Details

NCT06710379Recruiting

A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors

The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0405 in patients with select advanced solid tumors....

Duarte, CAPHASE168 participantsAdcentrx Therapeutics

View Study Details

NCT06190886Recruiting

A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors

The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of PTX-912 in patients with locally advanced or metastatic solid tumors. To evaluate the PK and immunogen...

Duarte, CAPHASE126 participantsProviva Therapeutics, Inc.

View Study Details

NCT05204147Recruiting

Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers

This phase I study tests the safety, side effects, and best dose of Ac225-DOTA-M5A in treating patients with CEA positive colorectal cancer that has spread to other places in the body (advanced). Ac22...

Duarte, CAPHASE120 participantsCity of Hope Medical Center

View Study Details

About Advanced Solid Tumors Clinical Trials in Duarte

Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.

There are currently 35 advanced solid tumors clinical trials recruiting participants in Duarte, CA. These studies are seeking a combined 10,367 participants. Research is being sponsored by Daiichi Sankyo, Astellas Pharma Inc, Incyte Corporation and 27 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Advanced Solid Tumors Clinical Trials in Duarte — FAQ

Are there advanced solid tumors clinical trials in Duarte?

Yes, there are 35 advanced solid tumors clinical trials currently recruiting in Duarte, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Duarte?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Duarte research site will contact you about next steps.

Are clinical trials in Duarte free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Duarte studies also compensate for your time and travel.

What advanced solid tumors treatments are being tested?

The 35 active trials in Duarte are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.

Data updated July 20, 2026 from ClinicalTrials.gov